ZYME Zymeworks Inc.
$28.90▲ +0.17%
Healthcare
Other
After hours
$28.91▲ +0.05%
Oct 28, 4:46 PM ET
Volume 833.1K
Avg Volume (10D) 1.23M
Key Metrics & Fundamentals
Market Cap
$2.08B
P/E Ratio
–
Div Yield
0.00%
52W Range
16.00 - 31.34
% vs 50 MA
6.13%
% vs 200 MA
14.78%
RSI-14
62.7
MACD Histogram
+0.3900
Beta (1Y vs SPY)
0.84
Free Cash Flow
-$31.95M
Gross Rev
$4.59M
Gross Profit
$4.59M
EBITDA
-$36.74M
COGS
–
Operating Exp
$46.74M
Operating Income
-$42.15M
EBIT
-$42.15M
Pretax Income
-$45.29M
Net Income
-$45.02M
EPS (Diluted)
-0.62
Price & Volume History
Loading chart…
Recent News
Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside
MarketBeat · Oct 27, 2026 7:04 PM ET
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
Business Wire · Oct 27, 2026 7:00 AM ET
How Investors Are Reacting To Zymeworks (ZYME) Roche Licensing Deal
Simply Wall St. · Oct 26, 2026 6:18 PM ET
Another autoimmune CAR-T death; Treasury zeroes in on China deals
BioPharma Dive · Oct 26, 2026 9:59 AM ET
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
GlobeNewswire · Oct 24, 2026 2:30 AM ET
Stocktwits Biotech Dealmaker: Gilead And Roche Double Down On Early-Stage Assets Over Full Buyouts This Week
Stocktwits · Oct 23, 2026 8:01 PM ET
Zymeworks stock surges on $813M Roche licensing deal
Investing.com · Oct 23, 2026 9:25 AM ET
Sector Update: Healthcare Stocks Fall Premarket Friday
MT Newswires · Oct 23, 2026 9:14 AM ET
Zymeworks Signs Roche Deal with $55 Million Upfront, Up to $718 Million in Milestones
MT Newswires · Oct 23, 2026 6:49 AM ET
Zymeworks Enters into an Exclusive Global License and Collaboration Agreement with Roche for ZW209, a Trispecific T cell Engager Targeting DLL3
GlobeNewswire · Oct 23, 2026 6:00 AM ET
Financial Overview - Income Statement
Quarterly
Jun 2026
See ZYME's money flow as a full page
Social Sentiment
Loading Reddit posts…
AI Analysis
Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.
Not financial advice.
All data, scores, charts, and analysis on this site are provided for informational and educational
purposes only and do not constitute financial, investment, legal, or tax advice.
Past performance is not indicative of future results.
See our Legal Notice for full details.